Table 2:
Patient demographicsa
| Definite PML (n = 16) | Possible PML (n = 4) | Control Cohort(n = 40) | |
|---|---|---|---|
| Sex (F/M) | 5:11 | 1:3 | 16:24 |
| Age (mean) (SD) (yr) | 46.4 (9.21) | 45.8 (8.46) | 43.6 (21.04) |
| Cause of PML | |||
| HIV | 13 (81.25%) | 3 (75%) | – |
| Cancer | 2 (12.5%) | 0 (0%) | – |
| Immunosuppressant therapy | 1b (6.25%) | 1c (25%) | – |
| Ethnicity | |||
| Hispanic | 1 (6.25%) | 0 (0%) | 2 (5%) |
| Non-Hispanic | 8 (50%) | 1 (25%) | 25 (62.5%) |
| Unknown | 7 (43.75%) | 3 (75%) | 13 (32.5%) |
| Race | |||
| White | 10 (62.5%) | 0 (0%) | 30 (75%) |
| African American | 2 (12.5%) | 2 (50%) | 3 (7.5%) |
| Asian | 0 (0%) | 0 (0%) | 1 (2.5%) |
| Unknown | 4 (25%) | 2 (50%) | 6 (15%) |
a
Patients with PML with positive JCV-CSF findings were defined as having definite PML. Patients with PML without CSF samples but with clinical and MR findings indicative of PML were defined as having possible PML.
b
Rituxan and fludarabine.
c
Mycophenolate mofetil (Cellcept), tacrolimus (FK-506), and prednisone.